133 related articles for article (PubMed ID: 15321023)
1. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits.
Dong JQ; Babusis DM; Welty DF; Acheampong AA; Tang-Liu D; Whitcup SM
J Ocul Pharmacol Ther; 2004 Aug; 20(4):285-92. PubMed ID: 15321023
[TBL] [Abstract][Full Text] [Related]
2. Formulation effects on ocular absorption of brimonidine in rabbit eyes.
Acheampong AA; Small D; Baumgarten V; Welty D; Tang-Liu D
J Ocul Pharmacol Ther; 2002 Aug; 18(4):325-37. PubMed ID: 12222763
[TBL] [Abstract][Full Text] [Related]
3. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.
Pellinen P; Lokkila J
Ophthalmic Res; 2009; 41(2):118-22. PubMed ID: 19147999
[TBL] [Abstract][Full Text] [Related]
4. Absorption of brimonidine 0.1% and 0.15% ophthalmic solutions in the aqueous humor of cataract patients.
Cantor LB; WuDunn D; Catoira-Boyle Y; Yung CW
J Glaucoma; 2008; 17(7):529-34. PubMed ID: 18854728
[TBL] [Abstract][Full Text] [Related]
5. Preservative-free
Duru Z; Ozsaygili C
Cutan Ocul Toxicol; 2020 Mar; 39(1):21-24. PubMed ID: 31615279
[No Abstract] [Full Text] [Related]
6. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes.
Mundorf T; Wilcox KA; Ousler GW; Welch D; Abelson MB
Adv Ther; 2003; 20(6):329-36. PubMed ID: 15058750
[TBL] [Abstract][Full Text] [Related]
8. A Comparative Ocular Pharmacokinetics Study of Preservative-Free Latanoprost Unit-Dose Eye Drops and a Benzalkonium Chloride-Preserved Branded Product Following Topical Application to Rabbits.
Zhou T; Miao Y; Li Z; Lu P; Liang Z; Yang J; He J; Xia H; Zhang Z; Zhang J
J Ocul Pharmacol Ther; 2020 Sep; 36(7):522-528. PubMed ID: 32310714
[No Abstract] [Full Text] [Related]
9. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
10. Vitreous concentration of topically applied brimonidine-purite 0.15%.
Kent AR; King L; Bartholomew LR
J Ocul Pharmacol Ther; 2006 Aug; 22(4):242-6. PubMed ID: 16910864
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
Uusitalo H; Kaarniranta K; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():7-13. PubMed ID: 18752509
[TBL] [Abstract][Full Text] [Related]
12. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.
Shen J; Durairaj C; Lin T; Liu Y; Burke J
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1056-66. PubMed ID: 24448267
[TBL] [Abstract][Full Text] [Related]
13. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
[TBL] [Abstract][Full Text] [Related]
14. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
Acheampong AA; Shackleton M; Tang-Liu DD
Drug Metab Dispos; 1995 Jul; 23(7):708-12. PubMed ID: 7587958
[TBL] [Abstract][Full Text] [Related]
15. Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
Suzuki G; Kunikane E; Shigemi W; Shinno K; Kozai S; Kurata M; Kawamura A
Curr Eye Res; 2021 Mar; 46(3):380-386. PubMed ID: 32706598
[TBL] [Abstract][Full Text] [Related]
16. Increasing efficacy and reducing systemic absorption of brimonidine tartrate ophthalmic gels in rabbits.
Pang X; Li J; Pi J; Qi D; Guo P; Li N; Wu Y; Liu Z
Pharm Dev Technol; 2018 Mar; 23(3):231-239. PubMed ID: 28488447
[TBL] [Abstract][Full Text] [Related]
17. Effect of benzalkonium chloride on transscleral drug delivery.
Okabe K; Kimura H; Okabe J; Kato A; Shimizu H; Ueda T; Shimada S; Ogura Y
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):703-8. PubMed ID: 15671302
[TBL] [Abstract][Full Text] [Related]
18. Effect of Brimonidine on the B Cells, T Cells, and Cytokines of the Ocular Surface and Aqueous Humor in Rat Eyes.
Shin HY; Lee HS; Lee YC; Kim SY
J Ocul Pharmacol Ther; 2015 Dec; 31(10):623-6. PubMed ID: 26401980
[TBL] [Abstract][Full Text] [Related]
19. Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study.
Orii Y; Kunikane E; Yamada Y; Morioka M; Iwasaki K; Arimura S; Mizuno A; Inatani M
PLoS One; 2022; 17(12):e0277313. PubMed ID: 36454807
[TBL] [Abstract][Full Text] [Related]
20. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
